Aceto Corporation (ACET) News
Filter ACET News Items
ACET News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ACET News From Around the Web
Below are the latest news stories about ADICET BIO INC that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Reports Third Quarter 2023 Financial Results and Provides Business UpdatesREDWOOD CITY, Calif. & BOSTON, November 08, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023. |
Adicet Bio to Present at the 2023 Jefferies London Healthcare ConferenceREDWOOD CITY, Calif. & BOSTON, November 07, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London. |
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual MeetingREDWOOD CITY, Calif. & BOSTON, November 02, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023. |
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON, October 31, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023. |
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics ConferenceREDWOOD CITY, Calif. & BOSTON, October 04, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Bos |
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON, September 29, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on September 29, 2023. |
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingREDWOOD CITY, Calif. & BOSTON, September 27, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023. |
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Adicet Reports Second Quarter 2023 Financial Results and Provides Business UpdatesREDWOOD CITY, Calif. & BOSTON, August 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. |
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth ConferenceREDWOOD CITY, Calif. & BOSTON, August 02, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference being held from August 7-10, 2023 in Boston. |